Introduction
============

Dendritic cells (DCs), which are representative antigen-presenting cells (APCs), play a pivotal role in the modulation of the immune response to various antigens *via* toll-like receptors (TLRs) ([@B29]). Immature DCs capture and process antigens in the peripheral tissues ([@B4]). After antigen uptake, mature DCs migrate to draining lymph nodes, wherein they activate naïve T-cells by upregulating surface molecules, including CD80, CD86, major histocompatibility complex (MHC) class I, and MHC class II ([@B3]). In addition, mature DCs can secrete various immunoregulatory cytokines such as interleukin (IL)-12, IL-6, and IL-10, which are regulators of inflammatory responses, and activate innate immune cells ([@B9]). Thus, it is well accepted that DC serves as a crucial linker between innate and adaptive immune response ([@B16]). The activation of nuclear factor kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase (ERK), c-jun N-terminal kinase (JNK), and p38, *via* TLRs regulates the maturation and differentiation of DCs ([@B24]).

The recognition of microbial products such as lipopolysaccharide (LPS) is initiated by TLRs, which recruit various signaling molecules, including the adaptor molecules myeloid differentiation protein 88 (MyD88), tumor necrosis factor receptor-associated factor 6 (TRAF6) and MyD88 adapter-like (MAL), resulting in the activation of downstream signaling pathways such as MAPKs and NF-κB ([@B2]). Because TLR activation usually polarizes Th1 responses, TLR agonists are potent candidates for immune adjuvants in tumor therapy ([@B18]). Among these mentioned TLR agonists, TLR4 agonists are more suitable for immunostimulatory adjuvants due to the DC-based immune boosting potency *via* TLR4 signaling cascade ([@B20]).

Glycogen synthase kinase-3 (GSK-3) was first identified as a key regulator of the glycogen metabolism; it regulates various cellular processes such as apoptosis, differentiation, growth, cell motility, and embryonic development by modulating various substrates ([@B7]; [@B30]; [@B10]). Recent studies have shown the role of GSK-3 as a regulator of immune responses, including activation and differentiation of DCs and endotoxemia ([@B25]; [@B22]).

Fibronectin (FN) attachment proteins (FAPs) belong to a family of FN-binding glycoproteins that are expressed by several species of mycobacteria ([@B23]; [@B25], [@B26]; [@B28]). FAP is crucial for attachment and internalization of *Mycobacterium bovis* BCG and *M. avium* subsp. *avium* to tissue of host ([@B19]; [@B31]). These processes were proved to be a FAP-dependent process ([@B13]; [@B27]). *M. avium* subsp. *paratuberculosis* also expresses a FAP which mediates soluble FN binding ([@B28]). In a previous report, we had shown that FAP expressed by *M. avium* enhances the immune response *via* regulation of DCs ([@B14]). However, the detailed mechanism of the FAP-regulated immune response is less defined.

In this study, we have shown the direct interaction between FAP and TLR4 in BMDCs. The expression of surface markers, including CD80, CD86, MHC class I, and MHC class II, and pro- and anti-inflammatory cytokines by FAP is TLR4-dependently modulated. In addition, we identified that DC-mediated CD8^+^ T cell proliferation and cytotoxic T lymphocyte activity by FAP is *via* GSK-3.

Results
=======

FAP interacts with TLR4 in BMDCs
--------------------------------

Previously, it was shown that *M. avium* regulates the immune response through modulation of DC maturation ([@B15]). Furthermore, we determined that the *M. avium* protein FAP is quite effective in inducing DC maturation and Th1 polarization ([@B14]). However, the precise mechanism by which this antigen mediates immune stimulation has not been defined. A Th1 response is usually triggered by TLR activation in dendritic cells. Using confocal microscopy and co-immunoprecipitation assays, we found that FAP co-localizes and binds with TLR4 in BMDCs ([Figure 1](#F1){ref-type="fig"}). These data demonstrates that FAP interacts with TLR4. Next, we investigated whether FAP plays a role as one of the TLR4 ligands by using *TLR4*^-/-^ BMDCs. FAP activated MAPKs, including ERK, JNK, and p38, and NF-κB in the presence of TLR4, but this phenomenon was not observed in cells in which TLR4 was knocked out ([Supplemental Data Figure S1](#S1){ref-type="supplementary-material"}).

The expression of the pro-inflammatory cytokines (IL-12 and TNF-α) and the anti-inflammatory cytokine IL-10 was enhanced by FAP treatment in a TLR4-dependent manner, and GSK-3 is involved in the effect of FAP
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Next, we investigated whether stimulation of DCs with FAP affects the production of pro- and anti-inflammatory cytokine that modulate the polarization of Th1 and Th2 cells *via* TLR4. We analyzed the production of the pro-inflammatory cytokines IL-12 and TNF-α and that of the anti-inflammatory cytokine IL-10 in FAP-treated *TLR4*^+/+^ and *TLR4*^-/-^ BMDCs using the ELISA method. FAP treatment elevated the production of the pro-inflammatory cytokines IL-12 and TNF-α as well as that of the anti-inflammatory cytokine IL-10, but the increase in the production of those cytokines by FAP was impaired in the absence of TLR4 ([Figure 2A](#F2){ref-type="fig"}). Thus, the FAP-mediated cytokine production, which is crucial for the modulation of DC functions, was also regulated in a TLR4-dependent manner.

In a recent publication, M. Martin et al. provided an evidence that GSK-3 modulates various cytokines, including IL-12 and TNF-α, *via* TLR4 ([@B17]). Thus, we examined whether GSK-3 is involved in the modulation of the abovementioned cytokines in the presence of FAP. Inhibition of GSK-3 resulted in the reduction of the IL-12 and TNF-α production compared with the FAP-treated control, whereas the IL-10 production was dramatically enhanced ([Figure 2B](#F2){ref-type="fig"}). This result demonstrates that GSK-3 is one of signaling pathway involved in the cytokine modulation by FAP.

FAP induces the expression of co-stimulatory (CD80 and CD 86) and MHC class I and II molecules in *TLR4*^+/+^ BMDCs, but the expression of those molecules was impaired in *TLR4*^-/-^ BMDCs
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The activation of TLR4, one of the crucial proteins in innate and adaptive immune responses, by various stimuli leads to the maturation of DCs. Thus, we examined the effect of FAP on DC maturation by investigating the expression of surface markers using flow cytometry. We found increased expression of surface markers, including CD80, CD86, MHC class I, and MHC class II, in FAP-treated *TLR4*^+/+^ BMDCs, but this phenomenon was not observed in FAP-treated *TLR4*^-/-^ BMDCs ([Figure 3](#F3){ref-type="fig"}). However, the expression of the abovementioned surface markers was still activated by FAP in *TLR2*^-/-^ BMDCs ([Figure 3](#F3){ref-type="fig"}). In addition, FAP-mediated DC maturation was impaired in GSK-3 inhibitor-treated condition. From this result, we concluded that DC maturation mediated by FAP occurs *via* the TLR4 rather than the TLR2 signaling pathway, and FAP-mediated DC maturation is partly dependent on GSK-3.

FAP-treated DCs induce proliferation and CTL activity of CD 8^+^ T-cell *via* GSK-3 activity
--------------------------------------------------------------------------------------------

To determine whether the FAP-induced maturation of DCs affects T-cell activation, we performed a mixed lymphocyte reaction (MLR) assay using CD8^+^ T-cells of OT-1 TCR transgenic mice, which express a TCR specific for the MHC class I-restricted Ovalbumin (OVA) peptide 257-264 antigen (OVA~257-264~) in DCs ([@B8]). The proliferation of CFSE-labeled OVA-specific CD8^+^ T-cells co-cultured with FAP-treated DCs pulsed with OVA~257-264~ was significantly higher than that of T-cells co-cultured with untreated DCs pulsed with OVA~257-264~ ([Figure 4A](#F4){ref-type="fig"}). In addition, the FAP-mediated enhanced CD8^+^ T-cell proliferation was dramatically inhibited by the treatment with the GSK-3 inhibitor SB415286 ([Figure 4A](#F4){ref-type="fig"}). Above FAP-mediated CD8^+^ T-cell proliferation was not observed in the absence of TLR4 ([Supplemental Data Figure S2](#S1){ref-type="supplementary-material"}). These results show that FAP functions as an immunostimulator for DC-mediated CD8^+^ T-cell proliferation *via* TLR4-GSK-3 signaling cascade.

Next, we investigated whether FAP-mediated CD8^+^ T-cell proliferation causes cytotoxic T lymphocyte (CTL) responses. OVA-pulsed DCs reduced the population of CSFE-stained OVA-expressing EG7 tumor cells compared to non-pulsed DCs, and OVA-expressing EG7 tumor cells were significantly lysed in FAP-treated DCs pulsed with OVA~257-264~ ([Figure 4B](#F4){ref-type="fig"}, *upper*). Furthermore, this increased CTL activity by FAP was inhibited following GSK-3 inhibition ([Figure 4B](#F4){ref-type="fig"}, *upper*). However, FAP-mediated modulation of DCs did not affect the CTL responses against non-OVA-expressing EL4 tumor cells ([Figure 4B](#F4){ref-type="fig"}, *bottom*). From these data, we concluded that FAP-treated DCs pulsed with OVA~257-264~ potentiates the OVA-specific CTL activity *via* the GSK-3 signaling pathway.

FAP triggers DC-derived anti-tumor activity *in vivo*
-----------------------------------------------------

Among the many TLR agonists, TLR4 agonists have a promising potential as immunostimulatory adjuvants because TLR4 signaling strongly induces DC maturation ([@B12]). In addition, it has been well documented that the expression of TLR4 on DCs is crucial for the anti-tumor effects of DC-based immunotherapy ([@B6]). To determine the anti-tumor potential of immunization with FAP-treated DCs, mice were intraperitoneally injected 3 times (1 week apart) with immature DCs and OVA (1 µg/ml)-pulsed DCs (1 × 10^6^) treated with or without FAP (500 ng/ml), followed by subcutaneous injection of EG7 thymoma cells (1 × 10^6^) into the right lower back. Injection of DCs pulsed with OVA~257-264~ significantly reduced the size of the OVA-expressing EG7 tumors compared to tumors in mice receiving DCs that have not been pulsed with OVA ([Figure 5A](#F5){ref-type="fig"}). Interestingly, EG7 tumors in mice that received FAP-treated DCs pulsed with OVA were smaller than those in mice that received DCs pulsed with OVA ([Figure 5A](#F5){ref-type="fig"}). Consistent with this, the group of mice injected with FAP-treated OVA-pulsed DCs showed a significant prolongation of survival compared to mice injected with OVA-pulsed DCs or DCs that have not been pulsed with OVA ([Figure 5B](#F5){ref-type="fig"}).

Discussion
==========

Recently, studies on the regulation of the immune response by *M. avium* subsp. *paratuberculosis* have been reported ([@B15]; [@B14]). It is well known that *M. avium* subsp. *paratuberculosis* is crucial for Johne\'s disease in animals. In addition, on the basis of recent clinical trials, it is considered a possible cause of Crohn\'s disease, an inflammatory disease of the intestines. Crohn\'s disease is considered an autoimmune disease because the immune system attacks the gastrointestinal tract, causing chronic inflammation ([@B1]).

DCs function as a crucial player in the innate and adaptive immune response. Thus, anti-tumor immune responses to DC-based vaccination have been suggested and studied with regard to the above-mentioned DC functions. In this study, we demonstrated following novel properties of the *M. avium* subsp. *paratuberculosis* FAP. 1) FAP-mediated DC maturation is *via* TLR4. 2) FAP-mediated DC maturation is *via* GSK-3. 3) FAP could be utilized for DC-based cancer vaccine as an immune-enhancement adjuvant.

TLR4 agonists have a broad spectrum of immunoregulatory applications, e.g., as adjuvants for vaccine treatment of chronic viral infections and in tumor therapy ([@B6]). Although LPS, a representative agonist of TLR4, is appropriate for immune enhancement, it is not applicable for anti-tumor immunity due to the risk of endotoxemia. In a previous study, we had shown that FAP is less toxic to DCs *in vitro* ([@B14]). Due to the non-toxic effects on DCs, we suggest that FAP is a potentially suitable adjuvant for immunotherapy.

Although *M. avium* subsp. *paratuberculosis* is a dangerous pathogen threatening animals and humans, FAP is applicable for the enhancement of immunogenicity because of its immunostimulatory ability. Our study provides for the first time evidence that FAP is an efficient TLR4 agonist. Further research to elucidate the exact mechanism underlying the regulation of DCs by FAP is currently underway. A more precise understanding of the interrelationship between DCs and *M. avium* subsp. *paratuberculosis* will provide crucial information for the therapy of cancer.

Methods
=======

Animals and reagents
--------------------

We purchased 4- to 8-week-old male C57BL/6 mice from the Korean Institute of Chemistry Technology (Daejeon, Korea). C57BL/6 OT-1 T-cell receptor (TCR) transgenic mice, C57BL/6J *TLR2*^-/-^ (B6.129-Tlr2^tm1Kir^/J), and C57BL/10 *TLR4*^-/-^ (C57BL/10ScNJ) were purchased at 6-8 weeks of age from the Jackson Laboratory (Bar Harbor, ME). All mice were housed in a specific pathogen-free environment and used in accordance with the institutional guidelines for animal care. Recombinant murine granulocyte-macrophage colony-stimulating factor (rmGM-CSF) and rmIL-4 were purchased from R&D Systems (Minneapolis, MN). Cytokine enzyme-linked immunosorbent assay (ELISA) kits for murine IL-12p70, tumor necrosis factor-alpha (TNF-α), and IL-10 were purchased from R&D Systems. Fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated monoclonal antibodies (mAbs) used to detect the expression of TLR4, CD11c (HL3), CD80 (16-10A1), CD86 (GL1), I-A^b^ β-chain (AF-120.1), and H-2K^b^ (AF6-88.5) by flow cytometry, as well as isotype-matched control mAbs and the biotinylated anti-CD11c (N418) mAb were purchased from R&D Systems. Alexa568-conjugated rabbit IgG Ab and anti-mouse TLR4/MD-2 complex Ab were purchased from eBioscience, Inc. (San Diego, CA). Anti-phospho-ERK, anti-ERK, anti-phospho-p38, anti-phospho-JNK, and anti-I-κB Abs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Cell lines
----------

The cell lines EL4, a thymoma-derived cell line, and EG7, an OVA-expressing EL4 variant were purchased from the American Type Culture Collection (ATCC; Manassas, VA) and cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin, and 10 mM L-glutamine (all purchased from Invitrogen, Carlsbad, CA) at 37℃ in a 5% CO~2~ atmosphere.

Expression and purification of recombinant FAP
----------------------------------------------

Preparation of recombinant FAP has been described previously ([@B5]). Briefly, genomic DNA was isolated from the *M. avium* subsp. *paratuberculosis* JTC303 strain, and the DNA encoding FAP (MAP1569) was amplified by PCR. After purification of the PCR product, it was ligated into the pET-22b(+) vector digested with the NdeI and XhoI enzymes. Expression of FAP in transformed BL21(DE3) cells was induced with isopropyl-beta-D-thiogalactopyranoside (IPTG) (Promega, Madison, WI). The soluble FAP was extracted after cell disruption by sonication. FAP containing a C-terminal histidine tag was purified using Ni-nitrilotriacetic acid (NTA) resin (Qiagen, Chatsworth, CA). The FAP was dialyzed five times in 10 mM phosphate-buffered saline (PBS) (pH 7.2) using a Slide-A-Lyzer dialysis cassette with a 3-kDa cutoff (Pierce, Rockford, IL). After dialysis, contaminating endotoxin was removed using Detoxi-Gel Affinity Pak columns (Pierce, Rockford, IL). FAP was incubated with endotoxin removal resin overnight to remove LPS and concentrated with a Centricon device (2,000-Da cutoff; Millipore). Also, endotoxin was assayed under endotoxin-free experimental conditions using a *Limulus* amebocyte lysate pyrogen kit (Biowhittaker, Walkersville, MD). The experiments were conducted according to the manufacturer\'s protocol. The quantity of endotoxin in the FAP was ≤ 0.01 ng/mg. The final concentration of purified FAP was determined using a bicinchoninic acid protein assay kit (Pierce, Rockford, IL).

Generation and culture of DCs
-----------------------------

Primary culture of DCs was performed as previously described ([@B11]), with slight modification. Briefly, bone marrow (BM) was flushed from the tibiae and femurs of 6 to 8-week-old male C57BL/6 mice and depleted of red blood cells (RBCs) using a red blood cell lysing buffer (Sigma-Aldrich, St. Louis, MO). The cells were then plated in 6-well culture plates (1 ×10^6^ cells/ml; 2 ml per well) in RPMI 1640 supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 20 ng/ml rmGM-CSF, and 10 ng/ml rmIL-4 at 37℃ in 5% CO~2~. On days 3 and 5, the floating cells were gently removed from the cultures and fresh medium was added. On day 6 of the culture, non-adherent cells and loosely adherent proliferating DC aggregates were harvested and re-plated in 60-mm dishes (1 ×10^6^ cells/ml; 5 ml/dish) for stimulation and analysis. On day 7, 80% or more of the non-adherent cells expressed CD11c. In certain experiments, the DCs were labeled with bead-conjugated anti-CD11c mAb (Miltenyi Biotec, Gladbach, Germany) and then subjected to positive selection through paramagnetic columns (LS columns; Miltenyi Biotec), according to the manufacturer\'s instructions, to obtain highly-purified populations for subsequent analysis. The purity of the selected cell fraction was \> 90%.

Flow cytometric analysis
------------------------

On day 7, the BMDCs were harvested, washed with phosphate buffered saline (PBS), and resuspended in FACS washing buffer (2% FBS and 0.1% sodium azide in PBS). The cells were first blocked with 10% (v/v) normal goat serum for 15 min at 4℃ and then stained with PE-conjugated anti-H-2K^b^, anti-I-A^b^, anti-CD80, anti-CD86, anti-MHC class I, anti-MHC class II, or with FITC-conjugated anti-CD11c for 30 min at 4℃. Finally, the stained cells were analyzed using the FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA).

Mixed leukocyte reaction
------------------------

Transgenic OVA-specific CD8^+^ T-cells were purified from bulk splenocytes *via* negative selection by using a mouse CD8^+^ T-cell kit (Miltenyi Biotec). The purity of the obtained cell population was assessed to be \> 93% by flow cytometry after staining with a Cy5-conjugated anti-CD8 Ab. Briefly, the cells were resuspended in 5 µM carboxyfluorscein diacetate succinimidyl ester (CFSE) in DMSO and shaken for 10 min at room temperature. Next, the cells were washed once in pure FBS and twice in PBS with 10% FBS. DCs (1 ×10^5^) were then exposed to FAP for 24 h and subsequently co-cultured with 1 × 10^6^ CFSE-labeled T lymphocytes in 96-well, U-bottom plates. After 3 days, the cells were harvested, stained with a Cy5-labeled anti-CD8 monoclonal Ab (to gate OT-1 T-cells), and then assessed by flow cytometry.

*In vitro* cytotoxicity assays
------------------------------

To determine the effect of FAP on the induction of OVA-specific CTLs, cytotoxicity assays were performed. In mixed cultures, immature DCs, OVA-pulsed DCs, or OVA-pulsed FAP-treated DCs were first cultured with splenocytes of OT-1 TCR transgenic mice (1 ×10^6^ per well) for 72 h and then co-cultured with EL4 (1 ×10^6^, cells stained with 1 µM CFSE) or EG7 cells (1 ×10^6^ cells stained with 10 µM CFSE). After 4 h, the mixed lymphocyte tumor cultures were analyzed by flow cytometry.

Cytokine assay
--------------

Murine IL-12p70, TNF-α, and IL-10 were measured using an ELISA kit according to the manufacturer\'s instructions.

Confocal laser scanning microscopy
----------------------------------

The cells were permeabilized with 1% saponin for 3 min, stained with rabbit anti-FAP and rat anti-TLR4/MD2 Abs overnight at 4℃, and then stained with rabbit anti-FAP and mouse PE-conjugated anti-TLR4 antibodies overnight at 4℃, and then stained with Alexa568-conjugated anti-rabbit antibody for 1 h at room temperature. Cell morphology and fluorescence intensity were analyzed using the Zeiss LSM510 Meta confocal laser scanning microscope (Zeiss, Jena, Germany). Images were acquired using the LSM510 Meta software and processed using the LSM image examiner.

Co-immunoprecipitation analysis
-------------------------------

Co-immunoprecipitation analysis was performed as previously described ([@B21]), with slight modification. The cells were lysed in lysis buffer (0.5% NP-40, 1 mM EDTA, 50 mM Tris-HCl, pH 8.0, 120 mM NaCl), and the lysates were subjected to 10 min of microcentrifugation at 12,000 *g*. The supernatant was then incubated for 2 h at 4℃ with the anti-FAP Ab, after which the mixture was incubated for an additional 1 h at 4℃ with protein G-coupled sepharose beads (Amersham Pharmacia Biotech, Uppsala, Sweden). The resultant precipitates were subjected to SDS-PAGE and immunoblotted with anti-TLR4 Ab.

Immunoblot analysis
-------------------

In brief, cell lysates were subjected to SDS-PAGE and transferred to PVDF membranes. The PVDF membranes were then blocked with 5% nonfat milk in a washing buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Tween 20) and incubated with the indicated antibodies for 1 h at room temperature. The membranes were washed and incubated for 1 h at room temperature with the appropriate secondary antibodies conjugated with horseradish peroxidase (Amersham Pharmacia Biotech, Uppsala). Protein bands were visualized using an enhanced chemiluminescence system (Amersham Pharmacia Biotech, Uppsala).

Statistical analysis
--------------------

All experiments were repeated at least 3 times with consistent results. Unless otherwise stated, data are expressed as the mean ± SEM. Analysis of variance was used to compare experimental groups with control values, while comparisons between multiple groups were made using Tukey\'s multiple comparison tests (Prism 3.0 GraphPad software). A *P* value less than 0.05 was considered to indicate statistical significance.
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![FAP interacts with TLR4. (A) Co-localization of FAP and TLR4 on DCs. DCs were treated with FAP (500 ng/ml) for 30 min, fixed, and stained with rabbit anti-FAP and mouse PE-conjugated anti-TLR4 antibodies overnight at 4℃, and then stained with Alexa568-conjugated anti-rabbit antibody for 1 h at room temperature. Cell morphology and fluorescence intensity were analyzed using the Zeiss LSM510 Meta confocal laser scanning microscope. (B) Co-immunoprecipitation of FAP and TLR4. DCs were treated with FAP (500 ng/ml) for 30 min. Cells were harvested, cell lysates were immunoprecipitated with IgG and anti-FAP, and proteins were visualized by immunoblotting with an anti-TLR4 antibody.](emm-44-340-g001){#F1}

![The expression of the pro-inflammatory cytokines (IL-12 and TNF-α) and the anti-inflammatory cytokine IL-10 was enhanced by FAP treatment in a TLR4-dependent manner, and GSK-3 is involved in the effect of FAP. (A) *TLR4*^+/+^ and *TLR*^-/-^ BMDCs were stimulated with FAP (500 ng/ml). After 24 h, the concentrations of IL-12, TNF-α, and IL-10 were measured in the culture supernatants by ELISA. The mean (SEM) values shown represent 3 independent experiments. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001 compared with untreated *TLR4*^+/+^ BMDCs. (B) BMDCs were pretreated with or without the indicated GSK-3 inhibitor (SB415286) concentration for 30 min and then harvested after 24 h of incubation with FAP (500 ng/ml). The cytokine concentrations in culture supernatants were measured by ELISA. The mean ± SEM values shown represent 3 independent experiments. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001 compared with untreated BMDCs.](emm-44-340-g002){#F2}

![FAP induces the expression of MHC class I and II and co-stimulatory molecules (CD80 and CD 86) in wild type and *TLR2*^-/-^ BMDCs, but the expression of those molecules was impaired in *TLR4*^-/-^ BMDCs. On day 6 of culturing, BMDCs were pretreated with or without the indicated GSK-3 inhibitor (SB415286) concentration for 30 min and then harvested after 24 h of incubation with FAP (500 ng/ml). BMDCs were first gated for CD11c^+^ cells and analyzed by two-color flow cytometry. (A) FAP induces the expression of co-stimulatory molecules (CD80 and CD86) in wild type and *TLR2*^-/-^ BMDCs, but the expression of these molecules was impaired in *TLR4*^-/-^ BMDCs. The mean fluorescence intensity (MFI) of double-positive cells is shown for each panel. The mean ± SEM values shown represent 3 independent experiments. ^\*\*^*P* \< 0.01 compared with untreated BMDCs. (B) FAP induces expression of MHC class I and II in wild type and *TLR2*^-/-^ BMDCs, but the expression of these molecules was impaired in *TLR4*^-/-^ BMDCs. The mean fluorescence intensity (MFI) of double-positive cells is shown for each panel. The mean ± SEM values shown represent 3 independent experiments. ^\*^*P* \< 0.05 compared with untreated BMDCs.](emm-44-340-g003){#F3}

![FAP-treated DCs induce proliferation and CTL activity of CD 8^+^ T-cells *via* GSK-3 activity. (A) Immature DCs, OVA-pulsed DCs, OVA-pulsed FAP-treated DCs, or OVA-pulsed FAP + GSK-3 inhibitor-treated DCs were cultured with CFSE-labeled splenocytes of OT-1 T-cell receptor transgenic mice (1 × 10^6^ per well) for 72 h. After 3 days, the cells were harvested and stained with Cy5-labeled anti-CD8 monoclonal Ab and analyzed by flow cytometry. Histograms showing CD8^+^ T-cell proliferation as assessed by flow cytometry. The mean ± SEM values shown represent 3 independent experiments. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01 compared with immature DCs. (B) In mixed cultures, immature DCs, OVA-pulsed DCs, OVA-pulsed FAP-treated DCs, or OVA-pulsed FAP + GSK-3 inhibitor-treated DCs were cultured with splenocytes of OT-1 T-cell receptor transgenic mice (1 × 10^6^ per well) for 72 h and then co-cultured with EL4 (1 × 10^6^ cells stained with 10 µM CFSE) or EG7 (1 × 10^6^ cells stained with 10 µM CFSE) cells. After 4 hours, mixed lymphocyte tumor cultures were analyzed by flow cytometry. The percentage in M1 indicates CFSE-stained EG7 cells and that in M2 indicates lysed cell debris of CFSE-stained EG7 cells. The mean ± SEM values shown represent 3 independent experiments. ^\*^*P* \< 0.05 compared with immature DCs.](emm-44-340-g004){#F4}

![FAP triggers DC-derived anti-tumor activity *in vivo*. (A) Mice were intraperitoneally injected 3 times (1 week apart) with immature DCs and OVA (1 µg/ml)-pulsed DCs (1 × 10^6^) treated with or without FAP, followed by subcutaneous injection of EG7 thymoma cells (1 × 10^6^) into the right lower back. The tumor size was measured every 4 days, and the tumor mass was calculated. *n* = 4 mice/group. ^\*^*P* \< 0.05. (B) Survival of mice was recorded for up to 100 days, *n* = 4 mice/group.](emm-44-340-g005){#F5}
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